Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 20/20 | 0.68 |
| ▸ | SCN1A | P35498 | 19/20 | 0.68 |
| ▸ | SCN5A | Q14524 | 19/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783376 | 0.87 | SCN8A (0.69) | SCN8ASCN1ASCN5ANR1I2CYP1A2 | |
| SCHEMBL21783335 | 0.86 | SCN8A (0.69) | SCN8ASCN1ASCN5ANR1I2CYP1A2 | |
| SCHEMBL21783378 | 0.81 | SCN1A (1.00) | SCN8ASCN1ASCN5A | |
| SCHEMBL21783396 | 0.80 | SCN1A (0.68) | SCN8ASCN1ASCN5A | |
| SCHEMBL21783384 | 0.78 | SCN1A (0.67) | SCN8ASCN1ASCN5A | |
| Trifluoroacetic Acid SCHEMBL30047259 | 0.76 | SCN1A (0.89) | SCN8ASCN1ASCN5A | |
| Trifluoroacetic Acid SCHEMBL21955485 | 0.76 | SCN1A (0.89) | SCN8ASCN1ASCN5A | |
| SCHEMBL21783480 | 0.75 | SCN8A (0.51) | SCN8ASCN1ASCN5ANR1I2CYP1A2 | |
| SCHEMBL26442657 | 0.74 | SCN1A (0.87) | SCN8ASCN1ASCN5A | |
| SCHEMBL21783554 | 0.74 | SCN8A (0.70) | SCN8ASCN1ASCN5ANR1I2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020047323-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |